As an important class of therapeutic molecules in modern biopharmaceuticals, fusion proteins exhibit unique therapeutic potential by combining multiple distinct functional protein domains. Despite their tremendous theoretical application prospects, the production of fusion proteins still faces numerous challenges, particularly regarding glycosylation and aggregate formation. As a critical post-translational modification, glycosylation directly impacts protein stability, solubility, and biological function. Aggregation, in turn, severely compromises the quality and efficacy of fusion proteins throughout the manufacturing process. This paper provides an in-depth discussion of the challenges associated with glycosylation and aggregation in the bioproduction of fusion proteins, and proposes strategies to address these issues.
Glycosylation: A Key Determinant of Protein Function and Stability
Glycosylation is a major post-translational modification that involves the attachment of carbohydrate chains to amino acid residues of proteins. It not only improves protein solubility but also enhances stability and prevents protein aggregation under both in vitro and in vivo conditions. The primary types of glycosylation include N-linked and O-linked glycosylation, which occur via the nitrogen atom of asparagine (Asn) residues and the oxygen atom of serine (Ser) or threonine (Thr) residues, respectively.
Functions of N-Linked Glycosylation
Asparagine 297 (N297) in the CH2 domain of the Fc region represents a canonical N-glycosylation site. N-glycosylation structurally stabilizes the CH2 domain of IgG and increases the thermal stability of antibodies. Aglycosylated antibodies show significantly reduced thermal stability, rendering them more prone to unfolding and aggregation. Glycosylation enhances protein stability by shielding protease-sensitive regions or blocking aggregation through hydrophobic structural motifs.
Heterogeneity of Glycosylation
Glycosylation heterogeneity represents a common challenge in fusion protein production. This heterogeneity typically arises from variable expression levels of glycosylation-related enzymes and differential availability of their substrates within the endoplasmic reticulum (ER) and Golgi apparatus. Glycosylation heterogeneity not only affects protein function but may also lead to inconsistent pharmacological efficacy. Controlling the type and extent of glycosylation, especially under varying culture conditions, is therefore critical in fusion protein manufacturing. Glycosylation control can be achieved at multiple levels through optimization of host cells, culture process parameters, and selective downstream processing.
Protein Aggregation: A Hidden Threat to Fusion Protein Quality
Protein aggregates are multimeric structures formed by intermolecular interactions, which impair protein solubility, increase the risk of immunogenicity, and reduce therapeutic efficacy. Aggregation is particularly prominent in fusion proteins due to their large molecular size and interactions between distinct functional domains.
Origins of Aggregation
Aggregate formation can be induced by both extrinsic and intrinsic factors. Extrinsic factors include temperature fluctuations (e.g., freeze-thaw cycles), physical stress (e.g., stirring, filtration, or high-flow shear), solution pH, ionic strength, organic solvents, and metal ions. Intrinsic factors are largely related to inherent protein properties, such as susceptible amino acid residues (subject to cleavage, oxidation, deamidation, or isomerization), exposed hydrophobic regions, or charge imbalance.
For instance, in the HSA-hGH fusion protein, aggregation under acidic conditions is driven by colloidal instability rather than conformational instability. Modulation of culture conditions or addition of chemical excipients such as caprylic acid may help reduce aggregation at low pH.
Impacts of Protein Folding and Disulfide Bonding
Correct protein folding is essential to prevent aggregation. Disulfide bond formation is critical for maintaining the three-dimensional structural stability of proteins; however, disulfide bond rearrangement under certain conditions can promote protein aggregation. In fusion proteins, mismatched or incomplete disulfide bond formation is especially prone to causing intermolecular cross-aggregation. Studies on Fc-fusion proteins have demonstrated that N-glycosylation not only stabilizes protein structure but also reduces aggregate formation.
Aggregation and Pharmacological Activity
While the detrimental effects of aggregation on protein quality are well established, in some cases, the presence of aggregates may exert favorable effects on therapeutic outcomes. For example, in oral protein delivery, aggregates can protect proteins from degradation in the gastrointestinal tract, thereby improving oral bioavailability.
Strategies to Address Glycosylation and Aggregation Challenges
To tackle glycosylation and aggregation issues during fusion protein production, researchers have developed a range of strategies:
Optimization of Culture Conditions
Regulation of medium composition, culture temperature, pH, and other parameters enables effective control of glycosylation profiles and aggregate formation. For example, hyperosmotic media can enhance Fc-fusion protein production, albeit with reduced sialylation; supplementation with osmolytes such as betaine can restore glycosylation levels.
Engineered Host Cell Lines
Engineering host cell lines to modulate glycosylation represents an effective approach. Studies have shown that precise control of glycosylation patterns can be achieved by deleting or overexpressing specific glycosyltransferases. Genetic engineering of host cells to ablate the activity of certain glycosylation enzymes or supplement with exogenous glycosylation-modifying enzymes facilitates the production of fusion proteins with desired glycosylation profiles.
Aggregation Control and Removal
Aggregation can be mitigated using disaggregating agents, pH adjustment, and addition of chemical modifiers such as urea. For preformed aggregates, chromatographic separation techniques are routinely employed for purification.
High-Throughput Analysis and Quality Control
Modern bioanalytical techniques, including LC-MS/MS (liquid chromatography-tandem mass spectrometry), are widely used for glycosylation profiling, aggregate detection, and monitoring of protein modifications. These methods enable characterization of glycosylation isoforms and analysis of aggregation kinetics to evaluate protein stability and biological activity.
Outlook and Conclusion
The production of fusion proteins, particularly regarding glycosylation and aggregation control, still presents substantial challenges. However, advances in genetic engineering, cell culture technology, and analytical methodologies are progressively resolving these obstacles. Future optimization of cell culture conditions, engineering of host cells, and implementation of advanced analytical tools will significantly improve the efficiency and quality of fusion protein production, facilitating their broader clinical application.
Fusion protein manufacturing technology is evolving toward higher efficiency and precision, offering promising prospects for the biopharmaceutical industry. In the near future, fusion proteins are expected to play an increasingly important role in the treatment of cancer, immune disorders, and other diseases.
